ReviewCurrent rheumatology reports2020
Morbidity and Mortality of Large-Vessel Vasculitides.
Review in Current rheumatology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 15 citations in OpenAlex.
- Efficacy of leflunomide in active Takayasu arteritis: a randomized double-blind placebo-controlled trial : Takayasu arteritis clinical trial in China (TACTIC).BMC medicine · 2026Trial
- Quantitative imaging features of pulmonary artery involvement in Takayasu arteritis on computed tomography pulmonary angiography in patients with and without pulmonary hypertension.Quantitative imaging in medicine and surgery · 2026Article
- Quantitative assessment of intrapulmonary vessel volume by CTPA in vasculitis patients with pulmonary vascular involvement.BMC medical imaging · 2026Article
- Integrated bulk and single-cell transcriptomics identifies shared and specific immune signatures in Takayasu Arteritis.Arthritis research & therapy · 2025Article
- Insight Into the Role of NLRP3 Inflammasomes in Takayasu's Arteritis: Mechanisms and Targeted Pharmacotherapies.Reviews in cardiovascular medicine · 2025Review
- Impact of Geographic Location on Diagnosis and Initial Management of Takayasu Arteritis: A Tale of Two Cohorts from Italy and India.Diagnostics (Basel, Switzerland) · 2022Article
- Fecal S100A12 in Takayasu arteritis predicts disease activity and intestinal involvement.Rheumatology international · 2022Article
- The role of neutrophils in rheumatic disease-associated vascular inflammation.Nature reviews. Rheumatology · 2022Review
- Large-vessel vasculitis.Nature reviews. Disease primers · 2022Review
- Application progress of multiple imaging modalities in Takayasu arteritis.The international journal of cardiovascular imaging · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewGiant cell arteritis (GCA) and Takayasu arteritis (TAK) comprise the primary systemic large-vessel vasculitides. In these conditions, arterial stenosis, occlusion, aneurysm, and dissection can lead to severe disease-related consequences. This review focuses on disease-related manifestations of GCA and TAK, emphasizing the impact of these findings on long-term morbidity and mortality. RECENT
findingsVision loss remains a main contributor of morbidity in GCA. Non-invasive imaging allows for recognition of aortic disease in GCA but monitoring and intervention guidelines require further development. TAK represents a severe disease of early-onset with high risk of morbidity due to aortic, pulmonary, cardiovascular, and neurologic involvement. Overall, patients with GCA have similar mortality rates to comparators but mortality is notably higher than the general population in TAK. A multidisciplinary approach of expert subspecialists is required to assist with the complex care of patients with GCA and TAK in order to appropriately surveil, identify, and address the multi-faceted co-morbidities of these diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.